---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-323753"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2026-07-29T20:15:15+00:00"
generated_at: "2026-07-29T20:17:48.461189+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q2 revenue $71.6M (+22% YoY); MRD up 33%; raises FY MRD guidance; CSO transitions to consultant

## Summary
- Q2 revenue $71.6M (+22% YoY); MRD revenue $66.2M (+33% YoY); clonoSEQ volume 36,111 (+43% YoY).
- Net loss $39.9M (incl. $23.7M loss on OrbiMed settlement); adjusted EBITDA loss improved to $0.7M from $7.2M.
- Completed $345M zero-coupon convertible notes offering; repaid OrbiMed Purchase Agreement; cash $371.7M.
- Raised FY 2026 MRD revenue guidance to $268M-$278M (from $260M-$270M); total opex guidance narrowed to $350M-$355M.
- CSO and co-founder Harlan Robins transitions to strategic consultant role; no disagreements.

## SEC filing metadata
- accession: 0001193125-26-323753
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2026-07-29T20:15:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/0001193125-26-323753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/adpt-20260724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-323753
- JSON: https://secwatch.observer/filing/0001193125-26-323753.json
- Plain text: https://secwatch.observer/filing/0001193125-26-323753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.